World’s First! Verified the Efficacy and Safety of Immune Checkpoint Inhibitor “Opdivo” in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function -- Kindai University
Verified the efficacy of immune checkpoint inhibitor (Opdivo) in patients with advanced hepatocellular carcinoma (aHCC) and mild to moderate impairment of liver function (Child-Pugh B class). Kindai University School of Medicine led the international collaborative research for aHCC patients with liver dysfunction for which no treatment options were available before.
Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University
- Efficacy of molecular target drug Nivolumab verified in investigator-initiated clinical trial for use with CUP by hospital team from Kindai University’s Faculty of Medicine - Reductions by more than half in tumor size in over 20% of CUP patients observed - Nivolumab expected to become standard treatment for CUP cases with no standard treatment